SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?
Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.
Zacks
More News
Dyne Therapeutics Stock Tumbles After Hours: Here's Why
Dyne Therapeutics stock fell after hours after pricing an upsized $375M public offering of common stock.read more...
Benzinga
Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock
Dyne Therapeutics announced plans to raise $300 million through a public stock offering on Tuesday.
Stocktwits
SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space
Citi reiterated a ‘Sell’ rating on SRPT, citing the expected rise in competition within the Duchenne muscular dystrophy (DMD) exon-skipping market.
Stocktwits
DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?
Dyne gains momentum as FDA priority review for its lead DMD therapy and progress in its DM1 program strengthen confidence in its pipeline.
Zacks
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026...
Yahoo! Finance: News
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?
Key PointsDyne Therapeutics focuses on high-potential therapies for rare neuromuscular diseases using its proprietary FORCE platform...
Nasdaq News: Markets
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsDyne Therapeutics is leveraging its FORCE platform to target rare neuromuscular diseases with high unmet need...
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
Key PointsFCPM III sold 818,460 shares of Dyne Therapeutics last quarter; the estimated transaction value was $14.11 million based on average prices...